KNTC2 peptides and vaccines containing the same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 21, 2017
Grant Date -
Jan 14, 2016
app pub date -
Mar 11, 2014
filing date -
Mar 12, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2-derived peptides and modified versions thereof, provided such modified versions retain the requisite CTL inducibility of the original sequences.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully